Kenvue combines a portfolio of iconic, trusted consumer health brands with a global distribution footprint and consistently strong gross margins. Historically, it has generated substantial operating and free cash flow, enabling meaningful returns of capital. Its categories are generally defensive, tied to everyday health and hygiene needs, and the company has a clear strategic focus on science‑based innovation and digital transformation to support future growth and efficiency.

The main concerns center on financial quality rather than commercial relevance. Profitability has trended downward over several years, operating costs and interest expense have risen, and the balance sheet is now more leveraged with weaker liquidity and negative retained earnings. The sudden collapse in operating and free cash flow in the most recent year is particularly notable and introduces significant uncertainty until it is fully explained. In addition, competitive intensity, regulatory exposure, and changing consumer preferences remain ongoing business risks.

The outlook appears mixed. On one hand, Kenvue’s brand strength, category resilience, and strategic investments in innovation and digital capabilities provide a solid foundation for stabilizing and potentially improving performance over time. On the other hand, the company faces a period where it must repair margins, rebuild cash generation, and carefully manage a more leveraged and less liquid balance sheet. Future results will likely hinge on the success of cost‑saving programs, the tangible impact of new product launches and digital initiatives, and clear evidence that the recent cash‑flow disruption is temporary rather than a sign of deeper structural issues.